This new CPB states that bendamustine is considered medically necessary for the following when criteria are met: classical Hodgkin lymphoma, lymphocyte-predominant Hodgkin lymphoma, multiple myeloma, AIDS-related B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, gastric MALT lymphoma, mantle cell lymphoma, nongastric MALT lymphoma, primary cutaneous B-cell lymphoma, splenic marginal zone lymphoma, and Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma.